COSM

7.7 million contracted units added in under two weeks - Cana Laboratories' orderbook has grown from over 12 million units earlier this year to more than 32.7 million today Secured orders for 1.04 million units annually - 5.2 million over five years - under new agreements with Target Pharma Coverage extended to 11 therapeutic categories with the addition of cardiovascular and anti-infective, up from nine in June 2026 Agreements extending up to ten years provide long-term visibility on production volumes and associated cash flows Division targeted to generate over $10 million in recurring annual profit at full capacity CHICAGO, IL / ACCESS Newswire / September 15, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") ( NASDAQ:COSM ), a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, Cana Laboratories S.A. ("Cana"), has secured new five-year contract manufacturing agreements with Target Pharma totaling approximately 5.2 million units.

Prime Ledger engaged to structure an asset-specific, non-dilutive tokenized financing for CCX0722 - backed by intellectual property, with no issuance of Cosmos Health common stock Positions Cosmos Health among the earliest NASDAQ-listed healthcare companies pursuing tokenized IP-backed assets. CCX0722 is an ingestible, hydrogel-based medical device in development for weight management, using a mechanical mechanism with no systemic absorption Intellectual property owned outright, with patent applications advanced into the United States, Europe, Australia and Canada Addresses a global weight management market projected to reach $562.2 billion by 2033 (14.2% CAGR) - set against a broader tokenized real-world-asset market projected to reach $18.9 trillion by 2033 CHICAGO, IL / ACCESS Newswire / September 14, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") ( NASDAQ:COSM ), a diversified, vertically integrated global healthcare group, today announced that it has engaged Prime Ledger Inc. ("Prime Ledger"), a digital asset advisory and tokenization firm, to structure a tokenized financing backed by the Company's intellectual property in CCX0722, an ingestible hydrogel-based medical device in development for weight management.

500,000 contracted units of ROSARTIA annually / 2.5 million over five years through a new long-term agreement at wholly owned subsidiary Cana Laboratories Expands Cosmos Health's manufacturing presence in cardiovascular pharmaceuticals, adding production of statin-based lipid-lowering therapies to Cana's growing contract manufacturing portfolio Cumulative contract manufacturing orderbook increases to more than 27.5 million units, up from over 25 million units reported in June 2026 Further strengthens recurring cash flow visibility and expands Cana's long-term manufacturing relationships with established pharmaceutical companies CHICAGO, IL / ACCESS Newswire / September 11, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") ( NASDAQ:COSM ), a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, Cana Laboratories S.A. ("Cana"), has secured a new five-year contract manufacturing agreement with Viofar covering approximately 2.5 million units of ROSARTIA.

First orders received for the Company's veterinary antimicrobial line, which will be marketed under the brand name C-ScrubVet Formulated for dogs, cats, horses, companion and large animals, and supplied in a 500ml pump-dispenser bottle Sales have commenced in the United Kingdom, with additional European markets to follow from Q4 2026 Multichannel strategy initially focused on e-commerce, with planned expansion into pet store chains and veterinary clinics Certified under European standards EN 1656 and EN 1657 for bactericidal and fungicidal activity in veterinary use Manufactured in-house at Cana Laboratories' EU GMP-licensed, EMA-certified facility, consistent with the Company's vertically integrated model Extends the C-Scrub franchise beyond human healthcare, addressing the $69 billion global animal health market Expected to be one of several catalysts supporting the Company's previously issued 2029 guidance of $200.6 million in revenue, $44.2 million in adjusted EBITDA and $31 million in net income CHICAGO, IL / ACCESS Newswire / September 9, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") ( NASDAQ:COSM ), a diversified, vertically integrated global healthcare group, today announced that it has received its first orders for its veterinary antimicrobial line, which will be marketed under the brand name C-ScrubVet. C-ScrubVet Wash 4% CHDG is a veterinary antimicrobial cleanser containing 4% chlorhexidine digluconate, effective against bacteria, fungi and enveloped viruses.

A Comprehensive Corporate Summary — January 1, 2026 through August 31, 2026 Revenue record set three consecutive quarters: FY2025 $65.3M (+20%) → Q1 2026 $17.93M (+31%) → Q2 2026 $18.99M (+28.8%) → H1 2026 $36.91M (+29.7%). Annualized adjusted run-rate exceeds $75M.

$8 million senior secured ATW convertible note satisfied, together with all accrued interest, twelve months ahead of its August 2027 maturity and eliminating any further dilution Simplified capital structure, with no effective shelf registration statement or ATM program, and no structured warrants or variable interest rate instruments without a floor Operating cash requirements reduced by more than 30%, reflecting revenue growth, operating efficiencies, improved operating leverage and cost control Strong liquidity position, with a diversified asset base supporting the Company's next growth phase and Bitcoin holdings now in a gain position following recent market strength $5.0 million share repurchase program underway, following record second-quarter and first-half revenue, with momentum continuing into Q3 2026 CHICAGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") ( NASDAQ: COSM ), a diversified, vertically integrated global healthcare group, today announced that its $8.0 million senior secured convertible ATW note has been retired, and provided an update on its capital structure and operating cash requirements. These financial milestones come at a time of accelerating growth, with Cosmos Health delivering its highest second-quarter and first-half revenue in Company history, contribution from every core division and momentum continuing into Q3 2026.

Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories.

Cosmos Health Enters Saudi Arabia. Signs Exclusive Distribution Agreement With Innova Healthcare; Secures Purchase Order of 126,000 Sky Premium Life Units.

Digital subscription platform brings together the Company's proprietary consumer health products across consumer (B2C) and corporate (B2B) channels Customers can begin through one of three paths: a free nutritionist consultation, an AI-powered assistant, or building their own package Corporate offering supports employee wellness programs and corporate gifting through multi-recipient management, tiered volume pricing, centralized billing, and dedicated account management Future platform enhancements are expected to include AI-driven personalization and the potential integration of at-home testing and diagnostic kits Platform builds on the U.S. subscription launch of NOOR Collagen, which has delivered an early repeat purchase rate above 60% CHICAGO, July 27, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”)  (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it is actively developing a flexible, technology-driven subscription platform for its consumer health products, representing a significant step in the Company's broader technology-driven transformation. Designed around customer choice, the platform will allow customers to begin with a free consultation with a nutritionist, engage with an AI-powered assistant, or select products and build their own package.

Cosmos Health expands its Sky Premium Life partnership with Pharma Cell in Albania, with average monthly orders already exceeding 4,500 units, and projected to exceed 54,000 annually Products are distributed across Albania and recommended by doctors and healthcare professionals, supporting broad consumer access Expansion builds on the partnership launched in April 2025 and reflects Sky Premium Life's continued global growth CHICAGO, July 20, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”)  (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced an expansion of its partnership with Pharma Cell for the distribution of its Sky Premium Life brand in Albania. Building on the partnership the companies launched in April 2025, and reflecting the strong reception of Sky Premium Life in the Albanian market, the Company anticipates that orders under the expanded relationship will exceed 54,000 units on an annualized basis, with average monthly orders already exceeding 4,500 units.